| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.8 |
| mRNA | ABT-263 | FIMM | pan-cancer | AAC | -0.031 | 0.8 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.8 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.0086 | 0.9 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | Pazopanib | FIMM | pan-cancer | AAC | 0.035 | 0.9 |